TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, v...

by Martin Demarchi, Pierre Coliat, Kristi Mclendon, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Ang, Litha Jaison, Filip Deforce, Marie Paule Derde, Michael Jinwoo Kim, Lisa Soyeon Park, Alexandre Detappe, Xavier Pivot
Published 2021-08-01

Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting

by Xavier Pivot, Alexey Georgievitch Manikhas, Volodymyr Shamrai, Giorgi Dzagnidze, Hwoei Fen Soo Hoo, Viriya Kaewkangsadan, Fausto Petrelli, Cristian Villanueva, Jamie Kim, Sumita Pradhan, Litha Jaison, Peggy Feyaerts, Leonard Kaufman, Marie-Paule Derde, Filip Deforce, David G. Cox
Published 2023-01-01

A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

by Martin Demarchi, Pierre Coliat, Philippe Barthelemy, Roland Schott, Meher BenAbdelghani, Michael Kim, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Rui Xia Ang, Marie Paule Derde, Filip Deforce, Thierry Petit, Chris Schwabe, Chris Wynne, Lisa Soyeon Park, Xavier Pivot
Published 2021-01-01

Genetic characterization and therapeutic targeting of MYC-rearranged T cell acute lymphoblastic leukaemia.

by Milani, Gloria, Matthijssens, Filip, Van Loocke, Wouter, Durinck, Kaat, Roels, Juliette, Peirs, Sofie, Thénoz, Morgan, Pieters, Tim, Reunes, Lindy, Lintermans, Beatrice, Vandamme, Niels, Lammens, Tim, Van Roy, Nadine, Van Nieuwerburgh, Filip, Deforce, Dieter, Schwab, Claire, Raimondi, Susana, Dalla Pozza, Luciano, Carroll, Andrew J, De Moerloose, Barbara, Benoit, Yves, Goossens, Steven, Berx, Geert, Harrison, Christine J, Basso, Giuseppe, Cavé, Hélène, Sutton, Rosemary, Asnafi, Vahid, Meijerink, Jules, Mullighan, Charles, Loh, Mignon, Van Vlierberghe, Pieter
Published 2019

RUNX2 regulates leukemic cell metabolism and chemotaxis in high-risk T cell acute lymphoblastic leukemia.

by Matthijssens, Filip, Sharma, Nitesh D, Nysus, Monique, Nickl, Christian K, Kang, Huining, Perez, Dominique R, Lintermans, Beatrice, Van Loocke, Wouter, Roels, Juliette, Peirs, Sofie, Demoen, Lisa, Pieters, Tim, Reunes, Lindy, Lammens, Tim, De Moerloose, Barbara, Van Nieuwerburgh, Filip, Deforce, Dieter L, Cheung, Laurence, Kotecha, Rishi, Risseeuw, Martijn DP, Van Calenbergh, Serge, Takarada, Takeshi, Yoneda, Yukio, van Delft, Frederik W, Lock, Richard B, Merkley, Seth D, Chigaev, Alexandre, Sklar, Larry A, Mullighan, Charles G, Loh, Mignon L, Winter, Stuart S, Hunger, Stephen P, Goossens, Steven, Castillo, Eliseo F, Ornatowski, Wojciech, Van Vlierberghe, Pieter, Matlawska-Wasowska, Ksenia
Published 2021